Advances in high-throughput proteomic and genomic technologies enable deep, scalable characterization of circulating and tissue-derived biomarkers across large clinical cohorts. These approaches capture broad protein landscapes and provide quantitative reproducibility suitable for translational research. To interrogate cancer biology across disease stages and sample types, we developed a multi-omic workflow integrating high-throughput discovery-scale proteomics, targeted protein quantification, and
transcriptomic profiling across plasma and matched FFPE tissues from donors representing multiple cancer types.
